About Us
We are at a breakthrough moment for Alzheimer’s disease research and drug development. At Acumen, we are leveraging decades of learnings to deliver treatments that can truly impact everyone affected by this devastating disease. Alzheimer’s disease (AD) currently affects over 6 million people in the U.S. and approximately 32 million people worldwide. By 2050, these numbers are expected to roughly triple and healthcare costs in the U.S. alone will exceed 1 trillion dollars without effective measures to prevent or slow the disease. AD is now the sixth-leading cause of death in the U.S., and it is likely to continue rising in the absence of more efficacious treatments.